MeSH term
Frequency | Condition_Probility | Animals | 27 | 0.0 |
Humans | 84 | 0.0 |
United States | 2 | 0.0 |
Adult | 26 | 0.0 |
Aged | 22 | 0.0 |
Case-Control Studies | 24 | 0.0 |
Comparative Study | 19 | 0.0 |
DNA Repair/*genetics | 26 | 7.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
DNA-Binding Proteins/*genetics | 28 | 1.0 |
Female | 35 | 0.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
Genotype | 22 | 0.0 |
Male | 26 | 0.0 |
Middle Aged | 31 | 0.0 |
Polymerase Chain Reaction | 14 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 34 | 0.0 |
Risk Factors | 15 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Cell Line | 14 | 0.0 |
*Chromosome Aberrations | 3 | 0.0 |
DNA Repair/genetics | 6 | 3.0 |
DNA-Binding Proteins/genetics | 9 | 1.0 |
Research Support, Non-U.S. Gov't | 63 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
*Antigens, Nuclear | 3 | 2.0 |
*DNA Helicases | 11 | 5.0 |
*DNA Repair | 16 | 2.0 |
Mutation | 9 | 0.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
Telomere/*genetics/metabolism | 2 | 25.0 |
*Polymorphism, Genetic | 25 | 0.0 |
Polymorphism, Genetic | 10 | 0.0 |
Prognosis | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Cell Cycle Proteins/genetics | 2 | 2.0 |
*Genetic Predisposition to Disease | 9 | 0.0 |
Haplotypes | 3 | 0.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Antineoplastic Agents, Alkylating/*pharmacology | 2 | 5.0 |
DNA Repair/*physiology | 2 | 1.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Amino Acid Sequence | 10 | 0.0 |
CHO Cells | 5 | 0.0 |
Chromosome Aberrations | 4 | 0.0 |
Cross-Linking Reagents/pharmacology | 2 | 1.0 |
*DNA Damage | 8 | 1.0 |
Genetic Complementation Test | 4 | 0.0 |
Hamsters | 12 | 0.0 |
Mitomycin/pharmacology | 2 | 2.0 |
Molecular Sequence Data | 13 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Transfection | 4 | 0.0 |
DNA Repair | 7 | 1.0 |
Smoking/*adverse effects | 3 | 1.0 |
Adolescent | 4 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Breast Neoplasms/epidemiology/*genetics | 3 | 2.0 |
Carbon-Oxygen Lyases/*genetics | 3 | 50.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
DNA-(Apurinic or Apyrimidinic Site) Lyase | 2 | 3.0 |
G2 Phase/genetics/radiation effects | 2 | 66.0 |
Polymorphism, Restriction Fragment Length | 10 | 0.0 |
Radiation Tolerance/*genetics | 3 | 5.0 |
Risk Assessment | 3 | 0.0 |
Time Factors | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism/physiology | 2 | 12.0 |
Gamma Rays | 2 | 0.0 |
Hela Cells | 9 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
Precipitin Tests | 7 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 20 | 0.0 |
DNA Damage | 10 | 1.0 |
X-Rays | 2 | 1.0 |
Baculoviridae/genetics | 2 | 1.0 |
DNA, Single-Stranded/metabolism | 2 | 3.0 |
Microscopy, Electron | 2 | 0.0 |
Protein Binding | 8 | 0.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Recombination, Genetic | 14 | 1.0 |
Blotting, Western | 3 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Insects | 2 | 1.0 |
Disease Progression | 2 | 0.0 |
Cross-Linking Reagents/*pharmacology | 2 | 8.0 |
*Recombination, Genetic | 5 | 1.0 |
Chromosomes/*genetics | 2 | 2.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 2 | 2.0 |
Carcinoma, Squamous Cell/genetics | 2 | 3.0 |
DNA Helicases/genetics | 3 | 14.0 |
Lung Neoplasms/*genetics | 4 | 1.0 |
Odds Ratio | 7 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Prospective Studies | 3 | 0.0 |
Proteins/*genetics | 5 | 0.0 |
*Transcription Factors | 8 | 0.0 |
Mice | 6 | 0.0 |
Regression Analysis | 4 | 0.0 |
Base Sequence | 6 | 0.0 |
DNA Primers | 5 | 0.0 |
Two-Hybrid System Techniques | 5 | 0.0 |
Alleles | 5 | 0.0 |
Exons | 3 | 0.0 |
Smoking | 2 | 0.0 |
Codon | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Saccharomyces cerevisiae/genetics | 3 | 0.0 |
Cattle | 2 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
*Endonucleases | 3 | 3.0 |
Logistic Models | 2 | 0.0 |
Nurses | 2 | 25.0 |
Smoking/adverse effects | 4 | 1.0 |
DNA, Complementary | 2 | 0.0 |
Cisplatin/pharmacology | 3 | 1.0 |
Cloning, Molecular | 3 | 0.0 |
Cosmids | 2 | 0.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
DNA Ligases/genetics | 2 | 22.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Cisplatin/*pharmacology | 2 | 1.0 |
Gene Frequency | 4 | 0.0 |
Proteins/genetics | 3 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Risk | 2 | 0.0 |
Hydrolysis | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Finland/epidemiology | 2 | 1.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
*Occupational Exposure | 3 | 2.0 |
Neoplasms/genetics/physiopathology | 2 | 22.0 |
Sensitivity and Specificity | 2 | 0.0 |
Chickens | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Enzymes/*genetics | 2 | 4.0 |
